Navigation Links
Gene therapy is a 'disruptive science' ready for commercial development
Date:1/24/2012

New Rochelle, NY, January 24, 2012The time for commercial development of gene therapy has come. Patients with diseases treatable and curable with gene therapy deserve access to the technology, which has demonstrated both its effectiveness and feasibility, says James Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy in a provocative commentary and accompanying videocast. Human Gene Therapy and Human Gene Therapy (HGT) Methods are peer-reviewed journals published by Mary Ann Liebert, Inc..

Until recently, gene therapy has been reserved for severe diseases with few treatment options. But the recent report of its successful use to treat hemophilia B, which would offer patients a therapeutic alternative that could replace the need for regular, lifelong protein replacement infusions, has brought gene therapy to the forefront as a technology capable of competing with and disrupting traditional forms of treatment. Although gene therapy for hemophilia B is still in early-stage clinical testing, a similar approach is in development to treat hemophilia A, and together these life-threatening diseases represent a $6.5 billion market for current protein replacement therapies.

The technical feasibility of gene therapy "has been established in multiple diseases and with different technology platforms," says Dr. Wilson, in the Commentary "It's Time for Gene Therapy to Get Disruptive!" He predicts that "2012 will usher in an era of commercial development of gene therapy that, although likely to begin slowly, will quickly gather momentum."

"The scientific community has been promising for years that disruptive change would follow from investments in biomedical research, such as the doubling of NIH and the sequencing of the human genome," says Terence R. F
'/>"/>

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Researchers develop gene therapy that could correct a common form of blindness
2. Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy
3. Springer in book partnership with American Society of Gene & Cell Therapy
4. Tapping the bodys own defenses, researchers look to cutting-edge gene therapy for bladder cancer
5. Insulin therapy may help repair atherosclerotic lesions in diabetic patients
6. Wayne State study finds soybean compounds enhances effects of cancer radiotherapy
7. When standard treatment fails: Jefferson to start unique immunotherapy for brain tumor patients
8. Toward a therapy to healing stroke
9. Thermotherapy rids azaleas of deadly fungal disease
10. Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
11. Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy is a 'disruptive science' ready for commercial development
(Date:9/19/2014)... Durante of dinosaurs a newly discovered hadrosaur ... dinosaur, named Rhinorex condrupus by paleontologists ... University, lived in what is now Utah approximately ... period. , Rhinorex, which translates roughly into "King ... of other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. ...
(Date:9/19/2014)... researchers from several Harvard University labs in collaboration ... aspiring researchers with the intellectual raw materials needed ... soft, flexible materials. , With the advent of ... in manufacturing technology, soft robotics is emerging as ... conventional rigid robot design, but working with pliable ...
(Date:9/19/2014)... the unique bioelectric signaling system of the electric fish, ... The OU researcher is working to understand how these ... used to map the world around them. Electric ... discharges a second throughout their lives. The energetic ... necessary for survival. , "There is evidence that electric ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... Company Anticipates Acquisition Could More Than Double its Current ... the Medical and Healthcare Industry, SAN JOSE, Calif., ... a leading biometric and security,solutions provider, announced today the ... Medical Systems (OTC: CHSY), a company listed in,the US ...
... The gigantic fossil claw of an 390 million-year-old sea scorpion, ... insects, crabs and the like were surprisingly larger than ... O. Erik Tetlie , postdoctoral associate in the Department of ... of the report online in Royal Society Biology Letters. The ...
... Newly launched nerve cells in a growing embryo must chart ... use to navigate have yet to surface. In a study published ... Salk Institute for Biological Studies have recovered a key signal that ... spinal cord and must find their way down the length of ...
Cached Biology News:Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 2Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 4Salk scientists identify key nerve navigation pathway 2Salk scientists identify key nerve navigation pathway 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/20/2014)... September 20, 2014 MediVet America ... perform a groundbreaking surgery at the specialized Wolvega Horse ... superficial digital flexor tendon was ruptured 90% and her ... injury is a death sentence for a horse. , ... stem cell treatments . This revolutionary regenerative option ...
(Date:9/19/2014)... Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... Memorandum of Understanding to settle the litigation in the ... Plan of Merger dated as of August 22, 2014, ... Inc.  As one term of the Memorandum of Understanding, ... forth in the attached exhibit reflecting the amendment to ...
Breaking Biology Technology:Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
... 25 Scimitar Equity, LLC issues a ... VOQP), entitled,"Creating Value; Turnaround Leverages Product Opportunities ... review is available at website: http://www.scimitarequity.com ... Jersey-based biotechnology company,dedicated to becoming a recognized ...
... 25 Mymetics,Corporation (OTC: MYMX), will be holding an ... PM New York Time to update all shareholders,on the ... Form 10-Q and to,address recent press articles., You ... at +1-866-591-4361 PIN 815,726 and from Europe at +41-800-329-326 ...
... 23 Eisai Corporation of,North America and its ... Food and Drug Administration (FDA) has approved a ... prevention of,chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules ... prevention of acute nausea and,vomiting following initial and ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 3